From the biology of trauma to secondary preventive pharmalogical measures for post-traumatic stress disorders;De la biologie du trauma aux pistes pharmacologiques de prévention secondaire de l'état de stress post-traumatique

Encephale

Volumn 31, Issue 2, 2005, Pages 212-226

  Ducrocq, F ^a   Vaiva, G ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Immediate treatment; Psychopharmacology; PTSD; Risk factors; Secondary prevention

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTALARMIN; ANTICONVULSIVE AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CLONIDINE; CORTICOSTEROID ANTAGONIST; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CYCLOSERINE; EGLUMETAD; FLUMAZENIL; GABAPENTIN; GUANFACINE; HYDROXYZINE; LAMOTRIGINE; MIRTAZAPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEFAZODONE; NEUROPEPTIDE Y; OPIATE AGONIST; PICROTOXIN; PRASTERONE; PRAZOSIN; PREGABALIN; PROPRANOLOL; RILUZOLE; SEROTONIN UPTAKE INHIBITOR; TIANEPTINE; TOPIRAMATE; VALPROIC ACID; VASOPRESSIN RECEPTOR ANTAGONIST;

ANXIETY DISORDER; COMORBIDITY; DEPRESSION; FAMILY LIFE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; NEUROBIOLOGY; OCCUPATION; POSTTRAUMATIC STRESS DISORDER; PRIMARY PREVENTION; PSYCHOPHARMACOLOGY; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SOCIAL LIFE; SUBSTANCE ABUSE;

EID: 18744377186     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0013-7006(05)82388-7     Document Type: Review

References (137)

1. ALBUCHER RC, LIBERZON I. Psychopharmacological treatment in PTSD: a critical review. J Psychiatr Res 2002; 36: 355-67.
2. ALONSO J, ANGERMEYER MC, BERNERT S et al. European Study of the Epidemiology of Mental Disorders (ESEMeD) Project. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 2004; 420: 21-7.
3. ANAND A, CHARNEY DS, OREN DA et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of Nmethyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000; 57: 270-6.
4. ANDERSEN TW, GRAVENSTEIN JS. Cardiovascular effects of sedative doses of phenobarbital and hydroxyzine. Anesthesiology 1966; 27 (3): 272-8.
5. ARNSTEN AFT. Catecholamine modulation of prefrontal cortical cognitive function. Trends Cogn Sci 1998; 2: 436-47.
6. ASHTON H, YOUNG AH. GABA-ergic drugs: exit stage left, enter stage right. J Psychopharmacol 2003; 17: 174-8.
7. BAGLEY J, MOGHADDAM B. Temporal dynamics of glutamate efflux in the prefrontal cortex and in the hippocampus following repeated stress: effects of pretreatment with saline or diazepam. Neuroscience 1997; 77: 65-73.
8. BALLENGER JC, DAVIDSON JR, LECRUBIER Y et al. Consensus statement update on post-traumatic stress disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 2004; 65 (1): 55-62.
9. BANDELOW B, ZOHAR J, HOLLANDER E et al. World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-traumatic Stress Disorders. World J Biol Psychiatry 2002; 3: 171-99.
10. BERIGAN TR. Gabapentin and PTSD. J Clin Psychiatry 2002; 63: 744.
11. BERLANT J, VAN KAMMEN DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian post-traumatic stress disorder: a preliminary report. J Clin Psychiatry 2002; 63: 15-20.
12. BLANK T, NIJHOLT I, ECKART K et al. Priming of long-term potentiation in mouse hippocampus by corticotropin-releasing factor and acute stress: Implications for hippocampus-dependent learning. J Neurosci 2002; 22: 3788-94.
13. BONNE O, GRILLON C, VYTHILINGAM M et al. Adaptive and maladaptive psychobiological responses to severe psychological stress: implications for the discovery of novel pharmacotherapy. Neurosci Biobehav Rev 2004; 28 (1): 65-94.
14. BRANNON N, LABBATE L, HUBER M. Gabapentin treatment for post-traumatic stress disorder. Can J Psychiatry 2000; 45: 84.
15. BRAUN P, GREENBERG D, DASBERG H et al. Core symptoms of post-traumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry 1990; 51: 236-8.
16. BREMNER JD, VYTHILINGAM M, VERMETTEN E et al. MRI and PET study of deficits in hippocampal structure and function in women with childhood sexual abuse and post-traumatic stress disorder. Am J Psychiatry 2003; 160: 924-32.
17. BREMNER JD, INNIS RB, SOUTHWICK SM et al. Decreased benzodiazepine receptor binding in prefrontal cortex in combat related post-traumatic stress disorder. Am J Psychiatry 2000; 157: 1120-6.
18. BREMNER JD, SOUTHWICK SM, CHARNEY DS. The neurobiology of post-traumatic stress disorder: an integration of animal and human research. In: Saigh PA, Bremner JD, eds. Post-traumatic Stress Disorder: a Comprehensive Text. New York: Allyn & Bacon, 1999: 103-43.
19. BRESLAU N. Epidemiology of trauma and post-traumatic stress disorder. In: Yehuda R, ed. Psychological Trauma. Washington (DC): American Psychiatric Press Inc, 1998.
20. BREWIN CR, ANDREWS B, VALENTINE JD. Meta-analysis of risk factors for post-traumatic stress disorder in trauma-exposed adults. J Consult Clin Psychol 2000; 68 (5): 748-66.
21. BRYANT RA. Early predictors of post-traumatic stress disorder. Biol Psychiatry 2003; 53 (9): 789-95.
22. BURGHARDT NS, SULLIVAN GM, McEWEN BS et al. The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine. Biol Psychiatry 2004; 55 (12): 1171-8.
23. BUTLER PD, WEISS JM, STOUT JC et al. Corticotropin-releasing factor produces fear-enhancing and behavioural activating effects following infusion into the locus coeruleus. J Neurosci 1990; 10: 176-83.
24. CAHILL L, PRINS B, WEBER M et al. Beta-adrenergic activation and memory for emotional events. Nature 1994; 371: 702-4.
25. CHAMBERS RA, BREMNER JD, MOGHADDAM B et al. Glutamate and post-traumatic stress disorder: Toward a psychobiology of dissociation. Sem Clin Neuropsych 1999; 4: 274-81.
26. CHAPPEL PB, SMITH MA, KILTS CD et al. Alterations in corticotropin- releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress. J Neurosci 1990; 6: 2908-14.
27. CICCONE PE, MAZAREK A, WEISBROT M et al. Am J Psychiatry [letter], 1988; 145: 1484-5.
28. COOK CJ. Glucocorticoid feedback increases the sensitivity of the limbic system to stress. Physiol Behav 2002; 75: 455-64.
29. CORDERO MI, SANDI C. A role for brain glucocorticoid receptors in contextual fear conditioning: dependence upon training intensity. Brain Res 1998; 786: 11-7.
30. COUPLAND NJ, LILLYWHITE A, BELL CE et al. A pilot controlled study of the effects of flumazenil in post-traumatic stress disorder. Biol Psychiatry 1997; 41: 988-90.
31. CZEH B, MICHAELIS T, WATANABE T et al. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc Natl Acad Sci USA 2001; 98 (22): 12796-801.
32. DAVIDSON JR. Long-term treatment and prevention of post-traumatic stress disorder. J Clin Psychiatry 2004; 65: 44-8.
33. DAVIDSON JR, WEISLER RH, BUTTERFIELD MI et al. Mirtazapine vs placebo in post-traumatic stress disorder: a pilot trial. Biol Psychiatry 2003; 53 (2): 188-91.
34. DAVIS LL, JEWELL ME, AMBROSE S et al. A placebo-controlled study of nefazodone for the treatment of chronic post-traumatic stress disorder: a preliminary study. J Clin Psychopharmacol 2004; 24 (3): 291-7.
35. DAVIS M, SHI C. The extended amygdala: are the central nucleus of the amygdala and the bed nucleus of the stria terminalis differentially involved in fear versus anxiety? Ann NY Acad Sci 1999; 877: 281-91.
36. DEAK T, NGUYEN KT, EHRLICH AL et al. The impact of the non-peptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 1999; 140: 79-86.
37. DIETRICH D, KRAL T, CLUSMANN H et al. Presynaptic group II metabotropic glutamate receptors reduce stimulated and spontaneous transmitter release in human dentate gyrus. Neuropharmacology 2002; 42: 297-305.
38. DUCROCQ F, VAIVA G, MOLENDA S et al. Depression et état de stress post-traumatique: complication ou comorbidité? Stress Trauma 2004; 4: 113-20.
39. DUCROCQ F, VAIVA G, COTTENCIN O et al. Approches psychopharmacologiques de l'état de stress post-traumatique. Stress Trauma 2001; 1 (2): 69-82.
40. DUCROCQ F, VAIVA G, COTTENTIN O et al. État de stress post-traumatique, dépression post-traumatique et épisode dépressif majeur: la littérature. Encéphale 2001; XXVII: 159-68.
41. DUMAN RS, NAKAGAWA S, MALBERG J. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology 2001; 25: 836-44.
42. FAMULARO R, KINSCHERFF R, FENTON T. Propranolol treatment for childhood post-traumatic stress disorder: acute type. Am J Dis Child 1990; 142: 1244-7.
43. FELDMAN TB. Alprazolam in the treatment of post-traumatic stress disorder. J Clin Psychiatry 1987; 48: 5.
44. FERRERI M, HANTOUCHE EG. Recent clinical trials of hydroxyzine in generalized anxiety disorder. Acta Psychiatr Scand 1998; 393: 102-8.
45. FOA EB, DAVIDSON JRT, FRANCES A. The expert consensus guideline series: Treatment of post-traumatic stress disorder. J Clin Psychiatry 1999; 60 (16): 1-77.
46. FOA EB, KEANE TM, FRIEDMAN MJ. Treatment of post-traumatic Stress Disorder: Critical Reviews and Treatment Guidelines (preliminary draft for review & ommentary). International Society for traumatic stress studies, 1999.
47. GELPIN E, BONNE O, PERI T et al. Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry 1996; 57: 390-4.
48. GERACIOTI JR TD, BAKER DG, EKHATOR NN et al. CSF norepinephrine concentrations in post-traumatic stress disorder. Am J Psychiatry 2001; 158: 1227-30.
49. GRILLON C, CORDOVA J, LEVINE LR et al. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology 2003; 168 (4): 446-54.
50. GRILLON C, SOUTHWICK SM, CHARNEY DS. The psychobiological basis of post-traumatic stress disorder. Mol Psychiatry 1996; 1 (4): 278-97.
51. HAGEMAN I, ANDERSEN HS, JORGENSEN MB. Post-traumatic stress disorder: a review of psychobiology and pharmacotherapy. Acta Psychiatr Scand 2001; 104: 411-22.
52. HAMNER MB, BRODRICK PS, LABBATE LA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 2001; 13: 141-6.
53. HARMON RJ, RIGGS PD. Clonidine for post-traumatic stress disorder in preschool children. J Am Acad Child Adolesc Psychiatry 1996; 35: 1247-9.
54. HAWK LW, DOUGALL AL, URSANO RJ et al. Urinary catecholamines and cortisol in recent-onset post-traumatic stress disorder after motor vehicle accidents. Psychosom Med 2000; 62: 423-34.
55. HEILIG M, WIDERLOV E. Neurobiology and clinical aspects of neuropeptide Y. Crit Rev Neurobiol 1995; 9: 115-36.
56. HEILIG M, SODERPALM B, ENGEL JA et al. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology 1989; 98: 524-9.
57. HERTZBERG MA, BUTTERFIELD MI, FELDMAN ME et al. A preliminary study of lamotrigine for the treatment of post-traumatic stress disorder. Biol Psychiatry 1999; 45: 1226-9.
58. HORRIGAN JP. Guanfacine for PTSD nightmares. J Am Acad Child Adolesc Psychiatry 1996; 35: 975-6.
59. HUANG GF, BESSON J, BERNARD JF. Intravenous morphine depresses the transmission of noxious messages to the nucleus centralis of the amygdala. Eur J Pharmacol 1993; 236: 449-56.
60. HUTCHEON DE, SCRIABINE A, MORRIS L. Cardiovascular action of hydoxysine (ATARAX). J Pharmacol Exp Ther 1956; 118: 451-60.
61. KALINER M, SIGLER R, SUMMERS R et al. Effects of infused histamine: analysis of the effects of H-1 and H-2 histamine receptor antagonists on cardiovascular and pulmonary responses. J Allergy Clin Immunol 1981; 68 (5): 365-71.
62. KENT JM, MATHEW SJ, GORMAN JM. Molecular targets in the treatment of anxiety. Biol Psychiatry 2002; 52: 1008-30.
63. KESSLER RC, SONNEGA A, BROMET E et al. PTSD in the national comorbidity survey. Arch Gen Psychiatry 1995; 52: 1048-60.
64. KHAN S, LIBERZON I. Topiramate attenuates exaggerated acoustic startle in an animal model of PTSD. Psychopharmacology (Berl). 2004 Mar; 172 (2): 225-9. Epub 2003 Oct 30.
65. KIMONIDES VG, SPILLANTINI MG, SOFRONIEW MV et al. Dehydroepiandrosterone antagonizes the neurotoxic effects of corticosterone and translocation of stress-activated proteinkinase 3 in hippocampal primary cultures. Neuroscience 1999; 89: 429-36.
66. KIMONIDES VG, KHATIBI NH, SVENDSEN CN et al. Dehydroepiandrosterone and DHEA-sulfate protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc Natl Acad Sci USA 1998; 95: 1852-7.
67. KINZIE JD, LEUNG P. Clonidine in Cambodian patients with post-traumatic stress disorder. J Nerv Ment Dis 1989; 177: 546-50.
68. KISHIMOTO T, RADULOVIC J, RADULOVIC M et al. Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 2000; 24: 415-9.
69. KNIEST A, WIESENBERG C, WEBER B et al. The glutamate antagonist riluzole and its effects upon basal and stressinduced activity of the human hypothalamus-pituitary-adrenocortical system in elderly subjects. Neuropsychobiology 2001; 43: 91-5.
70. KOLB LC, BURRIS BC, GRIFFITHS S. Propranolol and clonidine in the treatment of the chronic post-traumatic stress disorders of war. In: van der Kolk BA, ed. Post-traumatic Stress Disorder: Psychological and Biological Sequelae. Washington, DC: American Psychiatric Press; 1984: 98-105.
71. KRYSTAL JH, BENNETT AL, BREMNER DJ et al. Toward a cognitive neuroscience of dissociation and altered memory functions in post traumatic stress disorder. In: Friedman MJ, Charney DS, Deutch AY, eds. Neurobiological and Clinical Consequences of Stress: From Normal Adaptation to PTSD. Philadelphia: Lippincott-Raven 1995: 239-69.
72. LADER M, SCOTTO JC. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology 1998; 139 (4): 402-6.
73. LEMIEUX AM, COE CL. Abuse-related post-traumatic stress disorder: evidence for chronic neuroendocrine activation in women. Psychosom Med 1995; 57: 105-15.
74. LIPPER SL. Carbamazepine in the treatment of post-traumatic stress disorder: Implications for the kindling hypothesis. In: Wolf ME, Mosnaim AD, eds. Post-traumatic stress disorder: Etiology, phenomelogy, and treatment. Washington, : American Psychiatric Press, 1990: 184-203.
75. LLORCA PM, SPADONE C, SOL O et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry 2002; 63 (11): 1020-7.
76. LUCASSEN PJ, FUCHS E, CZEH B. Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal dentate gyrus and temporal cortex. Biol Psychiatry 2004; 55 (8): 789-96.
77. MAES M, LIN AH, BONACCORSO S et al. Higher serum prolyl endopeptidase activity in patients with post-traumatic stress disorder. J Affect Disord 1999; 53: 27-34.
78. MAGARINOS AM, DESLANDES A, McEWEN BS. Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol 1999; 371: 113-22.
79. MALEK-AHMADI P. Gabapentin and post-traumatic stress disorder. Ann Pharmacother 2003; 37: 664-6.
80. McEWEN BS. Effects of adverse experiences for brain structure and function. Biol Psychiatry 2000; 48: 721-31.
81. McGAUGH JL. Memory-A century of consolidation. Science 2000; 287: 248-51.
82. McGAUGH JL, CASTELLANO C, BRIONI J. Picrotoxin enhances latent extinction of conditioned fear. Behav Neurosci 1990; 104: 264-7.
83. McGAUGH JL. Involvement of hormonal and neuromodulatory systems in the regulation of memory storage: Endogenous modulation of memory storage. Ann Rev Neurosci 1989; 12: 225-87.
84. McNALLY RJ. Psychological mechanisms in acute response to trauma. Biol Psychiatry 2003; 53 (9): 779-88.
85. MELLMAN TA, BYERS PM, AUGENSTEIN JS. Pilot evaluation of hypnotic medication during acute traumatic stress response. J Trauma 1998; 11 (3): 563-9.
86. MORGAN CA, KRYSTAL JH, SOUTHWICK SM. Toward early pharmacological post-traumatic stress intervention. Biol Psychiatry 2003; 53 (9): 834-43.
87. MORGAN CA, RASMUSSON AM, WINTERS B. Trauma exposure rather than post-traumatic stress disorder is associated with reduced baseline plasma neuropeptide-Y levels. Biol Psychiatry 2003; 54 (10): 1087-91.
88. MORGAN CA III, RASMUSSON A, WANG S et al. Cortisol and subjective distress in humans exposed to acute stress. Biol Psychiatry 2002;52:136-42.
89. MORGAN CA, HAZLETT G, WANG S et al. Symptoms of dissociation in humans experiencing acute, uncontrollable stress: a prospective investigation. Am J Psychiatry 2001; 158: 1239-47.
90. MORGAN CA III, WANG S, RASSMUSON A et al. Relationship among cortisol, catecholamines, neuropeptide-Y and human performance during exposure to uncontrollable stress. Psychosom Med 2001; 63: 412-22.
91. MORGAN CA III, WANG S, SOUTHWICK SM et al. Plasma neuropeptide-Y in humans exposed to military survival training. Biol Psychiatry 2000; 47: 902-9.
92. OZER EJ, BEST SR, LIPSEY TL et al. Predictors of post-traumatic stress disorder and symptoms in adults: a meta-analysis. Psychol Bull 2003; 129: 52-73.
93. PARKER LN, SACK J, FISHER DA et al. The adrenarche: prolactin, gonadotropins, adrenal androgens, and cortisol. J Clin Endocrinol Metab 1978; 46: 396-401.
94. PERUCCA E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16: 695-714.
95. PITMAN RK, SANDERS KM, ZUSMAN RM et al. Pilot study of secondary prevention of post-traumatic stress disorder with propranolol. Biol Psychiatry 2002; 51: 189-92.
96. PITMAN RK, ORR SP, LASKO NB. Effects of intranasal vasopressin and oxytocin on physiologic responding during personal combat imagery in Vietnam veterans with post-traumatic stress disorder. Psychiatry Res 1993; 48: 107-17.
97. POST RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992; 149: 999-1010.
98. PRIETO N. Épidémiologie du traumatisme psychique. In: De Clercq M, Lebigot F, eds. Les traumatismes psychiques. Paris: Masson, Médecine et psychothérapie, 2001: 66-77.
99. RAINNIE DG, BERGERON R, SAJDYK TJ et al. Corticotrophin releasing factor-induced synaptic plasticity in the amygdala translates stress into emotional disorders. J Neurosci 2004; 24 (14): 3471-9.
100. RANDALL PK, BREMNER JD, KRYSTAL JH et al. Effects of the benzodiazepine antagonist flumazenil in PTSD. Biol Psychiatry 1995;38:319-24.
101. RASKIND MA, THOMPSON C, PETRIE EC et al. Prazosin reduces nightmares in combat veterans with post-traumatic stress disorder. J Clin Psychiatry 2002; 63: 565-8.
102. RASMUSSON AM, HAUGER RL, MORGAN CA. Low baseline and yohimbine-stimulated plasma neuropeptide Y levels in combat-related PTSD. Biol Psychiatry 2000; 47: 526-39.
103. REDDEMANN L, FLATTEN G. Therapy of post-traumatic stress disorders. MMW Fortschr Med 2003; 145: 35-7.
104. RISSE SC, WHITTERS A, BURKE J et al. Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced post-traumatic stress disorder. J Clin Psychiatry 1990; 51: 206-9.
105. ROSE S, BISSON J, WESSELY S. Psychological debriefing for preventing post-traumatic stress disorder (PTSD) (Cochrane Review). In: The Cochrane Library, Issue, Oxford, 1: 2003.
106. ROSE S, BISSON J, WESSELY S. A systematic review of single-session psychological interventions (debriefing) following trauma. Psychother Psychosom 2003; 72 (4): 176-84.
107. SALA M, PEREZB J, SOLOFF P et al. Stress and hippocampal abnormalities in psychiatric disorders. Eur Neuropsychopharmacol 2004; 14: 393-405.
108. SAMUELIAN JC, BILLARDON M, GUILLOU N. Modification of cognitive functions by 2 anxiolytic treatments in patients suffering from generalized anxiety. Encephale 1995; 21 (2): 147-53.
109. SAXE G, STODDAR F, COURTNEY D et al. Relationship between acute morphine and the course of PTSD in children with burns. J Am Child Adolesc Psychiatry 2001; 40: 915-21.
110. SCHOENFELD FB, MARMAR CR, NEYLAN TC. Current concepts in pharmacotherapy for post-traumatic stress disorder. Psychiatr Serv 2004; 55 (5): 519-31.
111. SCHWARTZ JC, ARRANG JM, GARBARG M et al. Histaminergic transmission in the mammalian brain. Physiol Rev 1991; 71 (1): 1-51.
112. SCHWARTZ JC, ARRANG JM. Neurotransmitter and signal transduction: Histamine. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: The Fifth Generation of Progress. American College of Neuropsychopharmacology, 2002.
113. SCOTT LV, DINAN TG. Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications for the pathophysiology of depression. Life Sci 1998; 62: 1985-98.
114. SHALEV AY. Biological responses to disasters. Psychiatry Q 2000; 71: 277-88.
115. SHALEV AY, FREEDMAN S, PERI T et al. Prospective study of post-traumatic stress disorder and depression following trauma. Am J Psychiatry 1998; 155: 630-7.
116. SHALEV AY, SAHAR T, FREEDMAN S et al. A prospective study of heart rate response following trauma and the subsequent development of post-traumatic stress disorder. Arch Gen Psychiatry 1998; 55: 553-9.
117. SHALEV AY, PERI T, CANETTI L et al. Predictors of PTSD in injured trauma survivors: A prospective study. Am J Psychiatry 1996; 153: 219-25.
118. SIERLES FS, CHEN JJ, McFARLANE RE et al. Post-traumatic stress disorder and concurrent psychiatric illness: a preliminary report. Am J Psychiatry 1993; 140: 1177-9.
119. SMULEVICH AB, SYRKIN AL, DROBIZHEV MIU et al. Therapy of cardio-neurotic diseases in general practice: clinical experience with Atarax. Klin Med 1999; 77 (1): 43-6.
120. SOUTHWICK SM, BREMNER JD, RASMUSSON A et al. Role of norepinephrine in the pathophysiology and treatment of post-traumatic stress disorder. Biol Psychiatry 1999; 46: 1192-204.
121. STEIN DJ, BANDELOW B, HOLLANDER E et al. World Council of Anxiety WCA Recommendations for the long-term treatment of post-traumatic stress disorder. CNS Spectr 2003; 8: 31-9.
122. STUTZMANN JM, CINTRAT P, LADURON PM et al. Riluzole antagonizes the anxiogenic properties of the beta-carboline FG 7142 in rats. Psychopharmacology 1989; 99: 515-9.
123. URSANO RJ, FULLERTON CS, EPSTEIN RS et al. Peritraumatic dissociation and post-traumatic stress disorder following motor vehicle accidents. Am J Psychiatry 1999; 156: 1808-10.
124. VAIVA G, THOMAS P, DUCROCQ F et al. Low Post-trauma GABA Plasma Levels as a Predictive Factor in the Development of Acute Post-traumatic Stress Disorder. Biol Psychiatry 2004; 55 (3): 250-4.
125. VAIVA G, BOSS V, DUCROCQ F et al. Low post-trauma GABA plasma levels: a predictive factor of PTSD or mood depressive disorder? Chicago, IL. International Society for Traumatic Stress Studies (ISTSS), November 2003.
126. VAIVA G, BRUNET A, LEBIGOT F et al. Fright and other peritraumatic responses after a serious motor vehicle accident: prospective influence on acute PTSD development. Can J Psychiatry 2003; 48: 43-9.
127. VAIVA G, DUCROCQ F, JEZEQUEL K et al. Immediate treatment with propranolol decreases post-traumatic stress disorder two months after. Biol Psychiatry 2003; 54: 947-9.
128. VAN EMMERIK AA, KAMPHUIS JH, HULSBOSCH AM. Single session debriefing after psychological trauma: a meta-analysis. Lancet 2002; 360 (9335): 766-71.
129. VILLARREAL G, HAMILTON DA, PETROPOULOS H et al. Reduced hippocampal volume and total white matter volume in post-traumatic stress disorder. Biol Psychiatry 2002; 52: 119-25.
130. WALKER DL, DAVIS M. The role of amygdala glutamate receptors in fear learning, fear-potentiated startle, and extinction. Pharmacol Biochem Behav 2002; 71: 379-92.
131. WALKER DL, RESSLER KJ, LU KT et al. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 2002; 22: 2343-51.
132. WILLIAMS K. Subunit-specific potentiation of recombinant N-methyl-D-aspartate receptors by histamine. Mol Pharmacol 1994; 46 (3): 531-41.
133. YEHUDA R. Risk factors for post-traumatic stress disorder. Washington, DC: American Psychiatric Press, 1999.
134. YEHUDA R. Biological factors associated with susceptibility to post-traumatic stress disorder. Can J Psychiatry 1999; 44 (1): 34-9.
135. YEHUDA R, McFARLANE AC, SHALEV AY. Predicting the development of post-traumatic stress disorder from the acute response to a traumatic event. Biol Psychiatry 1998; 44 (12): 1305-13.
136. YEHUDA R, SOUTHWICK S, GILLER EL et al. Urinary catecholamine excretion and severity of PTSD symptoms in Vietnam combat veterans. J Nerv Ment Dis 1992; 180: 321-5.
137. ZATZICK DF, KANG SM, MÜLLER HG et al. Predicting post-traumatic distress in hospitalized trauma survivors with acute injuries. Am J Psychiatry 2002; 159: 941-6.